|
J Biol Chem, Vol. 275, Issue 2, 1344-1350, January 14, 2000
Regulation of T Cell Receptor- and CD28-induced Tyrosine
Phosphorylation of the Focal Adhesion Tyrosine Kinases Pyk2 and Fak by
Protein Kinase C
A ROLE FOR PROTEIN TYROSINE PHOSPHATASES*
Masahiro
Tsuchida,
Eric R.
Manthei,
Tausif
Alam,
Stuart J.
Knechtle, and
Majed M.
Hamawy
From the Department of Surgery, University of Wisconsin,
Madison, Wisconsin 53792
 |
ABSTRACT |
The T cell receptor (TCR)-CD3 complex and the
costimulatory molecule CD28 are critical for T cell function. Both
receptors utilize protein tyrosine kinases (PTKs) for the
phosphorylation of various signaling molecules, a process that is
critical for the function of both receptors. The PTKs of the focal
adhesion family, Pyk2 and Fak, have been implicated in the signaling of TCR and CD28. We show here evidence for the regulation of TCR- and
CD28-induced tyrosine phosphorylation of the focal adhesion PTKs by
protein kinase C (PKC). Thus, treating Jurkat T cells with the PKC
activator phorbol 12-myristate 13-acetate (PMA) rapidly and strongly
reversed receptor-induced tyrosine phosphorylation of the focal
adhesion PTKs. In contrast, PMA did not affect TCR-induced tyrosine
phosphorylation of CD3 or the PTKs Fyn and Zap-70. However, PMA
induced a strong and rapid dephosphorylation of the linker molecule for
activation of T cells. PMA failed to induce the dephosphorylation of
proteins in PKC-depleted cells or in cells pretreated with the PKC
inhibitor Ro-31-8220, confirming the role of PKC in mediating the PMA
effect on receptor-induced protein tyrosine phosphorylation. The
involvement of protein tyrosine phosphatases (PTPases) in mediating the
dephosphorylation of the focal adhesion PTKs was confirmed by the
failure of PMA to dephosphorylate Pyk2 in cells pretreated with the
PTPase inhibitor orthovanadate. These results implicate PKC in the
regulation of receptor-induced tyrosine phosphorylation of the focal
adhesion PTKs in T cells. The data also suggest a role for PTPases in
the PKC action.
 |
INTRODUCTION |
Optimal T cell activation requires signals initiated by the
TCR1·CD3 complex and the T
cell costimulatory molecule CD28 (1, 2). Thus, the concurrent ligation
of these receptors triggers signals that synergistically regulate the
function of T cells. Signals initiated following TCR and CD28 ligation
include the stimulation of protein tyrosine kinases (PTKs), the
generation of inositol triphosphate and diacylglycerol, the activation
of protein kinase C (PKC), the increase in intracellular
Ca2+, the activation of the Ras and Rho family of GTPases,
and the activation of the mitogen-activated protein kinase (MAPK)
cascades (1-3). Stimulated MAPKs translocate from the cytoplasm to the nucleus where they phosphorylate and in turn activate transcription factors such as c-Fos and c-Jun. The increase in intracellular Ca2+ stimulates the serine/threonine phosphatase
calcineurin, leading to the dephosphorylation of the transcription
factor c-NAFT and in turn to its activation and translocation to the
nucleus. Activated transcription factors bind to promoters of genes,
leading to the initiation of gene transcription.
In contrast to the extensive data available concerning the signals
involved in promoting receptor function, much less is known about the
mechanisms that down-regulate receptor signaling in T cells. There is
evidence, however, implicating the serine/threonine kinase PKC in
regulating receptor-initiated signaling in T cells. For example, PKC
activation by PMA has been shown to modulate profoundly TCR- and
CD28-mediated interleukin-2 production and T cell proliferation (4-8).
Interestingly, the effect of PKC stimulation by PMA in different types
of cells, including T cells, is bidirectional; thus, the stimulation of
PKC delivers a synergistic auxiliary signal for cell activation and a
negative signal for down-regulating receptor function (4, 5, 7, 9-11).
The nature and the sequence of the signals downstream of PKC that modulate receptor function are poorly understood. PKC activation by PMA
has been shown to induce the serine/threonine phosphorylation of
several proteins, including TCR and CD28, in T cells (7, 9, 12-15).
Such phosphorylation is thought to play a role in modulating CD28 and
TCR functions by blocking the activity of signaling molecules and by
modulating protein-protein interaction (9, 10, 16, 17). Recently,
PMA-activated PKC has also been shown to serine phosphorylate PTPases
in vivo and in vitro, leading to the modulation
of their enzymatic activity (13, 18-22). However, the role of
PKC-activated PTPases in receptor signaling in T cells has not been reported.
The phosphorylation of proteins on tyrosine residues by PTKs is a
mechanism of signaling for various receptors, including receptors on T
cells, and is critical for many cellular processes, including cell
differentiation, proliferation, adhesion, and migration (1, 3).
Recently, a new family of PTKs has been identified as the focal
adhesion PTK family. This family consists of the non-receptor,
proline-rich PTKs Fak (Focal adhesion
kinase) and Pyk2 (Proline-rich
tyrosine kinase 2, also designated CAK ,
RAFTK, FAK2, or CADTK) (23-30). These kinases have a molecular mass of 110-125 kDa and are closely related in their overall structures. Fak
is expressed in most tissues, whereas Pyk2 is expressed mainly in the
central nervous system and in cells and tissues derived from
hematopoietic lineages. Fak and Pyk2 become tyrosine-phosphorylated and
activated after the stimulation of various receptors including TCR
(23-25, 28, 30-44), and both kinases have been linked to the signaling pathways that regulate MAPKs (31, 33, 35, 45).
There is evidence implicating the focal adhesion PTKs Fak and Pyk2 in
receptor-initiated activation of T cells. Thus, Pyk2 became
tyrosine-phosphorylated after CD28 and after TCR ligation, whereas Fak
was phosphorylated after TCR but apparently not after CD28 ligation
(30, 32, 43, 46, 47). Importantly, coligating CD28 and TCR increased
the tyrosine phosphorylation of Pyk2, suggesting that this kinase may
have a role in the costimulatory process in T cells (46, 47). We show
in the present article that PKC activation by PMA reverses
receptor-induced tyrosine phosphorylation of the focal adhesion PTKs.
PMA added to cells activated for 5 min by TCR or CD28 ligation led to
the dephosphorylation of Pyk2 and Fak. In contrast, PMA did not affect
TCR-induced tyrosine phosphorylation of CD3 and of the PTKs Fyn and
Zap-70. However, PMA induced strong and rapid dephosphorylation of the
linker molecule LAT. The dephosphorylation of the focal adhesion PTKs
by PMA required PKC, as PMA failed to dephosphorylate proteins in
PKC-depleted cells or in cells pretreated with the PKC inhibitor
Ro-31-8220. The PTPase inhibitor orthovanadate completely abolished
PMA-induced dephosphorylation of the focal adhesion PTKs, thereby
suggesting a role for PTPases in the PMA effect. Together, the data
implicate PKC in the regulation of receptor-induced tyrosine
phosphorylation of the focal adhesion PTKs in T cells.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Sodium orthovanadate, PMA, and 4 -phorbol were
from Sigma. LumiGLO chemiluminescent substrate kit was purchased from
Kirkegaard & Perry Laboratories (Gaithersburg, MD). Ro-31-8220 was
obtained from Calbiochem. Anti-Zap-70 mAb, anti-PTP1C mAb, and
anti-PTP1D mAb were obtained from Transduction Laboratories (Lexington,
KY). Anti-CD3 mAb and anti-Fyn mAb were from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA). Goat anti-human IgG-coated
Immulan beads were from Biotecx Laboratories, Inc. (Houston, TX). The
sources of other materials were as described previously (39, 47, 48).
Cells--
Human peripheral blood lymphocytes were isolated from
healthy volunteers on Ficoll-Paque, washed with RPMI containing 10% fetal calf serum, and were then incubated with goat anti-human IgG-coated Immulan beads according to the manufacturer's
recommendations. Unbound cells (T cells) were collected, and
contaminating adherent cells were removed by incubating the cells in a
tissue culture flask for 30 min at 37 oC. T cell purity
was at least 98% as determined by flow cytometry (49).
Acute human T cell leukemia (Jurkat) cells, clone E6-1, were obtained
from American Type Culture Collection (Manassas, VA). Cells were
maintained in suspension in complete medium (RPMI supplemented with
10% heat-inactivated fetal calf serum, 4 mM L-glutamine, and antibiotic/antimycotic mixture) at 37 °C in 5% CO2
and were subcultured 3 times per week.
Cell Activation and Preparation of Cell Lysates--
T cell
activation was done as reported previously with some modification (39,
47, 48). To examine the effect of activating PKC on receptor-initiated
protein tyrosine phosphorylation, cells were incubated with 1 µg/ml
anti-CD3 mAb or 3 µg/ml anti-CD28 mAb, and the tubes were placed in a
37 °C water bath for 5 min. At 5 min, cells were either lysed
immediately, were treated with media only, or were treated with media
containing PMA (50 ng/ml, final concentration). The incubation was then
resumed for the indicated time at 37 °C. For analysis of proteins in
whole cell lysates (WCL), cells were lysed with boiling SDS-PAGE sample
buffer (final concentration: 75 mM Tris-HCl, pH 6.8, 2%
SDS, 10% glycerol). For immunoprecipitation studies, cells were lysed
with ice-cold lysis buffer (final concentrations: 10 mM
Tris-HCl, pH 7.5, 1% Triton X-100, 0.5% sodium deoxycholic acid, 50 mM NaCl, 50 mM NaF, 2 mM
Na3VO4, 0.5 unit/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride).
To study the effects of the PTPase inhibitor orthovanadate and the PKC
inhibitor Ro-31-8220, T cells were pretreated with these drugs at
37 °C for 30 and 90 min, respectively, and then stimulated with
anti-CD3 mAb as above. PKC depletion was as described previously
(47).
Immunoprecipitation and Immunoblotting--
This was done as
described previously with some modification (39, 47, 48). Briefly, 10 µg of rabbit anti-mouse Ig were incubated for 2 h with 50 µl
of protein A-agarose. After incubation, the beads were pelleted by
centrifugation and washed with ice-cold solubilization buffer. The
primary Ab was then added to the beads followed by the addition of cell
lysates from 6 × 106 cells. The mixture was gently
rotated for 2 h at 4 °C. After incubation, the beads were
pelleted by centrifugation and washed 5× with ice-cold solubilization
buffer. After the final centrifugation, the beads were resuspended in
2× SDS-PAGE sample buffer and boiled for 5 min. Immunoblotting was as
described previously (39, 47, 48).
 |
RESULTS |
Regulation of TCR-induced Tyrosine Phosphorylation of the Focal
Adhesion PTKs by PMA--
To investigate whether PKC regulates
TCR-induced tyrosine phosphorylation of the focal adhesion PTKs in T
cells, we examined the effect of the PKC activator PMA on
receptor-induced tyrosine phosphorylation of these PTKs. Thus, we
stimulated purified normal resting human T cells and Jurkat T cells
with anti-CD3 mAb for 5 min to allow proteins to become
tyrosine-phosphorylated and then added PMA. As previously reported,
stimulating normal resting human T cells (Fig.
1A) or Jurkat T cells (Fig.
1B) with anti-CD3 mAb for 5 min induced protein tyrosine
phosphorylation, determined by blotting WCL with anti-phosphotyrosine
mAb. Interestingly, the addition of PMA to the cells in the continuous
presence of the mAb for an additional 5 min (Fig. 1, A and
B, compare lanes 3 and 4) or 10 min
(Fig. 1, A and B, compare lanes 5 and
6) markedly decreased the phosphorylation of certain
proteins. In normal human T cells and in Jurkat T cells tyrosine
phosphorylation of a 110-, a 70-, and a 40-kDa protein was reproducibly
and most prominently affected by PMA. The dephosphorylation of the
proteins was rapid and strong, as it was apparent within 5 min of the
addition of PMA and was marked at 10 min. PMA effect was
dose-dependent and was not mimicked by the biologically
inactive 4 -phorbol (Fig. 1C, compare lanes 7 and 8).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
PMA reverses TCR-induced protein tyrosine
phosphorylation. 5 × 105 purified normal human T
cells (A) or Jurkat T cells (B) in RPMI
containing 0.001% BSA were lysed immediately with boiling sample
buffer (lane 1) or were stimulated for 5 min at 37 °C
with 1 µg/ml anti-CD3 mAb (lanes 2-6). After 5 min
incubation, cells were either lysed immediately with boiling sample
buffer (lane 2) or were treated with only media (lanes
3 and 5) or with media containing PMA (50 ng/ml; final
concentration) (lanes 4 and 6), and the
incubation was resumed for an additional 5 (lanes 3 and
4) or 10 min (lanes 5 and 6). After
boiling in sample buffer, proteins in WCL were separated by SDS-PAGE,
transferred to membranes, and immunoblotted with anti-phosphotyrosine
mAb ( -PY). Arrows indicate proteins that
become dephosphorylated after PMA treatment. C, 5 × 105 Jurkat T cells in RPMI containing 0.001% BSA were
lysed immediately with boiling sample buffer (lane 1) or
were stimulated for 5 min at 37 °C with 1 µg/ml anti-CD3 mAb
(lanes 2-8). After 5 min incubation, cells were either
lysed immediately with boiling sample buffer (lane 2) or
were treated with only media (lane 3) or with media
containing the indicated concentrations of PMA (lanes 4-7)
or with 50 ng/ml of 4 -phorbol (lane 8), and the
incubation was resumed for an additional 5 min. After boiling in sample
buffer, proteins in WCL were separated by SDS-PAGE, transferred to
membranes, and immunoblotted with anti-phosphotyrosine mAb
( -PY).
|
|
To examine the effect of PKC activation on receptor-induced tyrosine
phosphorylation of Pyk2 and Fak, Jurkat T cells were stimulated with
anti-CD3 mAb for 5 min and then treated with PMA as described above.
Pyk2 and Fak were immunoprecipitated and transferred to membranes, and
the membranes were then immunoblotted with anti-phosphotyrosine mAb or
with the specific antibodies. As reported previously, ligating CD3 with
a mAb increased tyrosine phosphorylation of Pyk2 and Fak (Fig.
2, A and B, upper
panel). Such phosphorylation declined with time after receptor
ligation, reaching background values within 30-60 min (not shown).
Strikingly, the addition of PMA to cells already stimulated for 5 min
with anti-CD3 mAb almost completely reversed Pyk2 and Fak tyrosine
phosphorylation (Fig. 2, A and B, compare
lanes 3 and 4). The dephosphorylation of Pyk2 and
Fak by PMA was rapid and strong, as the phosphorylation of the PTKs was
markedly reduced within 5 min of the addition of PMA. Reprobing the
membranes with anti-Pyk2 mAb (Fig. 2A, lower panel) or
anti-Fak mAb (Fig. 2B, lower panel) showed equal amounts of
proteins in all lanes, ruling out the possibility that incubating the
cells with PMA induced a selective degradation of the PTKs.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Down-regulation of TCR-induced tyrosine
phosphorylation of the focal adhesion PTKs by PMA.
A and B, 6 × 106 Jurkat T cells
in RPMI containing 0.001% BSA were lysed with ice-cold lysis buffer
(lane 1) or were stimulated with 1 µg/ml anti-CD3 mAb for
5 min at 37 °C (lanes 2-4). At 5 min, cells were either
lysed immediately with ice-cold lysis buffer (lane 2) or
were treated with only media (lane 3) or with media
containing PMA (50 ng/ml; final concentration) (lane 4), and
the incubation was resumed for an additional 5 min. After solubilizing
with ice-cold lysis buffer, proteins in cell lysates were
immunoprecipitated (IP) with the indicated mAb and were
analyzed by immunoblotting with anti-phosphotyrosine mAb ( -PY,
upper panel) or with the specific mAb (lower
panel).
|
|
PMA Fails to Induce the Dephosphorylation of CD3 or of the PTKs
Fyn and Zap-70--
Following TCR ligation, Src PTKs (including Fyn)
are rapidly activated, leading to the phosphorylation of the tyrosine
residues in the CD3 subunit of TCR and to the subsequent activation
of the PTK ZAP-70. To examine whether PKC activation under the same conditions that lead to the dephosphorylation of the focal adhesion PTKs also regulates tyrosine phosphorylation of molecules
phosphorylated early in the TCR signaling cascade, Jurkat T cells were
activated for 5 min with anti-CD3 mAb and then treated with PMA.
Proteins were then immunoprecipitated from cell lysates and examined
for tyrosine phosphorylation by blotting with anti-phosphotyrosine mAb
(Fig. 3, A-C, upper panels).
As shown in Fig. 3A, Fyn was strongly
tyrosine-phosphorylated in unstimulated cells, and its phosphorylation
increased only modestly upon CD3 aggregation. PMA treatment did not
appear to affect the receptor-induced tyrosine phosphorylation of Fyn
(Fig. 3A, compare lanes 3 and 4),
although a slight decrease was seen in some experiments. Similarly, PMA did not affect tyrosine phosphorylation of CD3 , as at 10 min there
was no difference in the tyrosine phosphorylation of CD3 in cells
treated with or without PMA (Fig. 3B, compare lanes
3 and 4). In contrast to CD3 and Fyn, Zap-70 was not
tyrosine-phosphorylated in unstimulated cells (Fig. 3C).
Ligating CD3 markedly increased the tyrosine phosphorylation of the
PTK. PMA addition to cells stimulated for 5 min with anti-CD3 mAb
failed to dephosphorylate Zap-70, as the extent of Zap-70 tyrosine
phosphorylation in untreated or in PMA-treated cells was similar (Fig.
3C, compare lanes 3 and 4). The
failure of PMA to induce the dephosphorylation of CD3 , Fyn, and
Zap-70 strongly suggests that PKC activation does not lead to general,
nonspecific regulation of receptor signaling.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 3.
PMA fails to induce the dephosphorylation of
CD3 , Fyn, or Zap-70 but rapidly
dephosphorylates LAT. A-D, 6 × 106
Jurkat T cells in RPMI containing 0.001% BSA were lysed with ice-cold
lysis buffer (lane 1) or were stimulated with 1 µg/ml
anti-CD3 mAb for 5 min at 37 °C (lanes 2-4). At 5 min,
cells were either lysed immediately with ice-cold lysis buffer
(lane 2), were treated with only media (lane 3),
or with media containing PMA (50 ng/ml; final concentration)
(lane 4), and the incubation was resumed for an additional 5 min. Proteins in cell lysates were immunoprecipitated (IP)
with the indicated mAb and were analyzed by immunoblotting with
anti-phosphotyrosine mAb ( -PY, upper panel) or with the
specific mAb (lower panel).
|
|
PMA Induces the Dephosphorylation of the Linker Molecule
LAT--
PMA strongly and reproducibly dephosphorylated ~40-kDa
proteins (Fig. 1). Recently, a 36-40-kDa linker molecule has been
identified as LAT (Linker for Activation of
T cells), which becomes tyrosine-phosphorylated upon TCR
and CD28 ligation (48, 50). Thus, we examined whether PMA
down-regulates receptor-induced LAT phosphorylation. As previously reported, ligating CD3 with a mAb increased tyrosine phosphorylation of
LAT (Fig. 3D, upper panel). Notably, the addition of PMA to cells already stimulated for 5 min with anti-CD3 mAb almost completely reversed LAT tyrosine phosphorylation (Fig. 3D, compare
lanes 3 and 4). The dephosphorylation of LAT by
PMA was rapid and strong, as the phosphorylation of LAT was markedly
reduced within 5 min of the addition of PMA. Reprobing the membranes
with anti-LAT mAb (Fig. 3D, lower panel) showed
equal amounts of proteins in all lanes, ruling out the possibility that
incubating the cells with PMA induced a degradation of the molecule.
Evidence for the Requirement of PKC for PMA Regulation of
Receptor-induced Protein Tyrosine Phosphorylation--
PKC is the
intracellular receptor for PMA and therefore is implicated in mediating
PMA effects on cells. PMA is a diacetylglycerol analogue that can
permeate biological membranes and directly bind to a cysteine-rich
region on PKC that is physiologically recognized by diacylglycerol,
leading to the sustained activation of the kinase. To confirm further
the role of PKC in mediating the down-regulation by PMA of receptor
signaling, cells were depleted of PKC by incubating for 16 h with
400 nM PMA. Such treatment effectively reduces
Ca2+-dependent and Ca2+-independent
PKC (Fig. 4A). As shown in
Fig. 4B, ligating CD3 in PKC-depleted cells induced an
increase in protein tyrosine phosphorylation. Importantly, freshly
added PMA to PKC-depleted cells failed to dephosphorylate these
proteins (Fig. 4B, compare lanes 3 and
4, and 7 and 8). To examine the effect
of PKC depletion on PMA regulation of Pyk2 tyrosine phosphorylation,
lysates from untreated or from PKC-depleted cells were
immunoprecipitated with anti-Pyk2 mAb and then immunoblotted with
anti-phosphotyrosine mAb (Fig. 4C, upper panel). As shown in
Fig. 4C, PMA failed to induce the dephosphorylation of Pyk2
in PKC-depleted cells (compare lanes 3 and
4, and 7 and 8). To confirm further
the involvement of PKC in the PMA effect, Jurkat T cells were treated
with the PKC inhibitor Ro-31-8220 and then treated with anti-CD3 mAb
and PMA. As shown in Fig. 5, A
and B, Ro-31-8220 blocked PMA-induced protein
dephosphorylation, including Pyk2, in a dose-dependent manner (compare lanes 2 and 3, 5 and
6, and 8 and 9). These results strongly implicate PKC in mediating PMA effects on receptor-induced tyrosine phosphorylation of Pyk2.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
PKC depletion blocks PMA effects on
receptor-induced protein tyrosine phosphorylation. A,
Jurkat T cells were incubated for 16 h with only media or with 400 nM PMA. To confirm PKC depletion, WCL were immunoblotted
with antibody to Ca2+-dependent PKC ,
Ca2+-independent PKC , and atypical PKC . B,
untreated cells (left panel) and cells pretreated with 400 nM PMA (right panel) were washed and then
suspended in RPMI containing 0.001% BSA. The cells were then lysed
immediately (lanes 1 and 5) or were stimulated
with anti-CD3 mAb for 5 min at 37 °C (lanes 2-4 and
6-8). At 5 min, the cells were lysed immediately
(lanes 2 and 6) or were treated with media only
(lanes 3 and 7) or with media containing PMA (50 ng/ml; final concentration) (lanes 4 and 8), and
the incubation was resumed for an additional 5 min. Phosphoproteins
were detected with anti-phosphotyrosine mAb ( -PY) as
described in Fig. 1. C, cell lysates from cells treated as
in B were precipitated with anti-Pyk2 mAb as described in
the legend for Fig. 2. Pyk2 in the precipitates was analyzed by
immunoblotting with anti-phosphotyrosine mAb ( -PY, upper
panel) or with the specific mAb (lower panel).
IP, immunoprecipitated.
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
The PKC inhibitor Ro-31-8220 blocks PMA
effects on receptor-induced protein tyrosine phosphorylation.
A, 6 × 106 Jurkat T cells in RPMI
containing 0.001% BSA were untreated (lanes 1-3) or
pretreated with 1.25 (lanes 4-6) or 2.5 µM
(lanes 7-9) Ro-31-8220 for 90 min at 37 °C. After
incubation, the cells were lysed immediately (lanes 1, 4, and 7) or were stimulated with anti-CD3 mAb for 5 min at
37 °C (lanes 2, 3, 5, 6, 8, and 9). At 5 min,
the cells were treated with media only (lanes 2, 5, and
8) or with media containing PMA (50 ng/ml; final
concentration) (lanes 3, 6, and 9), and the
incubation was resumed for an additional 5 min. Phosphoproteins were
detected with anti-phosphotyrosine mAb ( -PY) as described
in Fig. 1. B, lysates from cells activated as described
in A were precipitated with anti-Pyk2 mAb as described in
the legend for Fig. 2. Pyk2 in the precipitates was analyzed by
immunoblotting with anti-phosphotyrosine mAb ( -PY, upper
panel) or with the specific mAb (lower panel).
IP, immunoprecipitated.
|
|
Evidence for the Involvement of PTPases in PKC-mediated Regulation
of Receptor Signaling--
The dephosphorylation of the focal adhesion
PTKs by PMA implicates PTPases in the PMA effect. To study further the
involvement of PTPases in the PMA effect, we pretreated Jurkat T cells
for 30 min with the PTPase inhibitor sodium orthovanadate and then examined the effect of PMA on receptor-induced protein tyrosine phosphorylation. As shown in Fig.
6A, the inhibition of PTPases by orthovanadate led to a general increase in the basal level of
protein tyrosine phosphorylation in unstimulated cells in a dose-dependent manner (compare lanes 1, 4, and 7). Ligating CD3 in orthovanadate-treated cells
induced protein tyrosine phosphorylation. However, the phosphorylation
was less apparent in cells pretreated with high concentration of
orthovanadate, which was most likely due to the increase in the basal
level of protein tyrosine phosphorylation. Interestingly, PMA failed to
dephosphorylate proteins in orthovanadate-treated cells (Fig.
6A, compare lanes 2 and 3, 5 and
6, and 8 and 9). To examine the effect
of orthovanadate treatment on PMA regulation of Pyk2 tyrosine
phosphorylation, lysates from untreated or from orthovanadate-treated
cells were immunoprecipitated with anti-Pyk2 mAb and then immunoblotted
with anti-phosphotyrosine mAb (Fig. 6B, upper panel). As
shown in Fig. 6B, orthovanadate also led to the increase in
the basal level of Pyk2 tyrosine phosphorylation in unstimulated cells
(compare lanes 1, 4, and 7), suggesting that Pyk2
tyrosine phosphorylation is tightly regulated by PTPases. In
orthovanadate-treated cells, ligating CD3 with a mAb led to an increase
in the tyrosine phosphorylation of Pyk2 (Fig. 6B, compare
lanes 4 and 5, and 7 and
8). Importantly, orthovanadate pretreatment blocked Pyk2
dephosphorylation by PMA in a dose-dependent manner (Fig.
6B, compare lanes 2 and 3, 5 and
6, and 8 and 9). These data show that
PTPases are involved in the PKC regulation of receptor signaling in T
cells.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
The PTPase inhibitor sodium orthovanadate
(Na3VO4) blocks PKC-mediated regulation of
receptor-induced protein tyrosine phosphorylation. A,
6 × 105 Jurkat T cells in RPMI containing 0.001% BSA
were untreated (lanes 1-3), pretreated with 2 mM sodium orthovanadate (lanes 4-6), or with 4 mM sodium orthovanadate (lanes 7-9) for 30 min
at 37 °C. After incubation, the cells were lysed immediately
(lanes 1, 4, and 7) or were stimulated with
anti-CD3 mAb for 5 min at 37 °C (lanes 2, 3, 5, 6, 8, and
9). At 5 min, the cells were treated with media only
(lanes 2, 5, and 8) or with media containing PMA
(50 ng/ml; final concentration) (lanes 3, 6, and
9), and the incubation was resumed for an additional 5 min.
Phosphoproteins were detected with anti-phosphotyrosine mAb
( -PY) as described in Fig. 1. B, lysates from
cells activated as described in A were precipitated with
anti-Pyk2 mAb as described in the legend for Fig. 2. Pyk2 in the
precipitates was analyzed by immunoblotting with anti-phosphotyrosine
mAb ( -PY, upper panel) or with the specific mAb
(lower panel). IP, immunoprecipitated.
|
|
Regulation of CD28-induced Pyk2 Tyrosine Phosphorylation by
PMA--
We recently reported that ligating the T cell costimulatory
molecule CD28 with a mAb increases tyrosine phosphorylation of Pyk2 but
not Fak (47). We examined whether CD28-induced Pyk2 tyrosine
phosphorylation is also regulated by PMA-initiated signals. Stimulating
Jurkat T cells with anti-CD28 mAb (Fig.
7A) for 5 min induced protein
tyrosine phosphorylation, determined by blotting WCL with
anti-phosphotyrosine mAb. Importantly, the addition of PMA to the cells
in the continuous presence of the mAb for an additional 5 (Fig.
7A, compare lanes 3 and 4) or 10 min
(Fig. 7A, compare lanes 5 and 6)
markedly potentiated the dephosphorylation of receptor-induced protein
tyrosine phosphorylation. As shown in Fig. 7B, PMA rapidly
reversed tyrosine phosphorylation of Pyk2 induced by CD28 ligation
(compare lanes 3 and 4).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 7.
PMA-activated PKC regulates CD28-induced
tyrosine phosphorylation of Pyk2. A, 5 × 105 Jurkat T cells in RPMI containing 0.001% BSA were
lysed (lane 1) or were stimulated for 5 min at 37 °C with
3 µg/ml anti-CD28 mAb (lanes 2-6). After 5 min
incubation, cells were either lysed immediately with boiling sample
buffer (lane 2) or were treated with only media (lanes
3 and 5) or with media containing PMA (50 ng/ml; final
concentration) (lanes 4 and 6), and the
incubation was resumed for an additional 5 (lanes 3 and 4)
or 10 min (lanes 5 and 6). After boiling in
sample buffer, proteins in WCL were separated by SDS-PAGE, transferred
to membranes, and immunoblotted with anti-phosphotyrosine mAb
( -PY). B, 6 × 106 Jurkat T
cells in RPMI containing 0.001% BSA were lysed immediately with
ice-cold lysis buffer (lane 1) or were stimulated with 3 µg/ml anti-CD28 mAb for 5 min at 37 °C (lanes 2-4). At
5 min, cells were either lysed immediately with ice-cold lysis buffer
(lane 2), were treated with only media (lane 3),
or with media containing PMA (50 ng/ml; final concentration)
(lane 4), and the incubation was resumed for an additional 5 min. After solubilizing with ice-cold lysis buffer, proteins in cell
lysates were immunoprecipitated (IP) with anti-Pyk2 mAb and
were analyzed by immunoblotting with anti-phosphotyrosine mAb
( -PY, upper panel) or with the specific mAb (lower
panel).
|
|
 |
DISCUSSION |
The recently identified focal adhesion PTKs have been implicated
in the signal transduction pathways of TCR and CD28. In the present
study we showed evidence for the down-regulation of receptor-induced tyrosine phosphorylation of the focal adhesion PTKs by activated PKC as
follows: 1) PMA, a PKC activator, rapidly and strongly potentiated the
dephosphorylation of the PTKs; 2) PMA failed to dephosphorylate the
proteins in PKC-depleted cells or in cells treated with the PKC
inhibitor Ro-31-8220.
The rapid and strong dephosphorylation of focal adhesion PTKs upon PKC
activation strongly suggests that the tyrosine phosphorylation of these
PTKs is tightly regulated by PTPases. Recently, PMA-activated PKC has
been shown to serine phosphorylate PTPases in vivo and in vitro, leading in some cases to the modulation of their
enzymatic activity (13, 18-22). Thus, it is possible that PKC
activation is stimulating a PTPase(s) in Jurkat T cells that regulates
receptor-initiated protein tyrosine phosphorylation. However, PMA
treatment of Jurkat T cells did not lead to an increase in the PTPase
activity that coprecipitates with Pyk2, as determined by subjecting
Pyk2 immunoprecipitates to in vitro PTPase reactions using
the Promega tyrosine phosphatase assay system (Madison, WI) (data not
shown). Furthermore, we did not detect the PTPases PTP1C or PTP1D in
Pyk2 immunoprecipitates, and Pyk2 was not detected in the
immunoprecipitates of these PTPases (not shown). Alternatively, PKC
could be down-regulating tyrosine phosphorylation of the focal adhesion
PTKs by inhibiting a signaling event upstream of the tyrosine
phosphorylation of the focal adhesion kinase or by blocking the
activity of PTKs responsible for the phosphorylation of the focal
adhesion PTKs. This may prematurely terminate receptor signaling and,
in turn, allow for the dephosphorylation of the focal adhesion PTKs by
PTPases associated with these PTKs. Src kinases have been shown to
associate with focal adhesion PTKs and therefore have been implicated
in the tyrosine phosphorylation of the PTKs (30, 32, 33, 45, 51);
however, serine/threonine phosphorylation of Src kinases by
PMA-activated PKC has been studied extensively and has been shown not
to affect significantly the kinase activity of the Src PTKs (52-55).
Although in some of our studies, PMA induced a slight decrease in
receptor-induced tyrosine phosphorylation of Fyn, the decrease did not
correlate with the marked dephosphorylation of Pyk2 seen in all
experiments. Our data showed that PMA induced the dephosphorylation of
the linker molecule LAT. This molecule is thought to be important for
linking molecules tyrosine phosphorylated early in the TCR signaling
transduction pathways with downstream molecules (50). Thus, it is
possible that the dephosphorylation of LAT is interrupting the flow of signals that lead to the tyrosine phosphorylation of the focal adhesion
PTKs. However, at this time there is no evidence that LAT functions in
the signaling pathways upstream of the focal adhesion PTKs. Thus,
although our data strongly suggest that PTPases are involved in the PKC
action, it is not clear at this time whether PKC activation is leading
to the stimulation of PTPases or whether it is facilitating the
function of basal level phosphatases by inhibiting a signaling event(s)
upstream of the tyrosine phosphorylation of the focal adhesion PTKs.
TCR- and CD28-induced protein tyrosine phosphorylation declines with
time after receptor ligation, indicating that a mechanism exists for
down-regulating receptor signaling. Our data showed that PMA-induced
activation of PKC potentiated the dephosphorylation of LAT and of the
focal adhesion PTKs that became tyrosine-phosphorylated after TCR and
CD28 ligation. TCR and CD28 ligation has also been shown to initiate
signals that activate PKC. However, PMA is a global activator of PKC,
which binds directly to PKC and leads to the persistent activation of
the kinase. Thus, the potentiated dephosphorylation of LAT and of the
focal adhesion PTKs following PMA treatment of CD3- and CD28-activated
T cells could be due to the enhancement of PKC activation by PMA. This
issue awaits further investigation.
PKC activation by PMA appears to have different effects on the tyrosine
phosphorylation of the focal adhesion PTKs in different types of cells
(25, 34, 39, 41, 43, 47). PMA induced tyrosine phosphorylation of Pyk2
in rat pheochromocytoma (PC12) cells (25), in CMK megakaryotic cells
(38), and in human embryonic kidney 293 cells (25). Similarly, PMA led
to strong tyrosine phosphorylation of Fak in fibroblasts (41). In
contrast, PMA failed to induce tyrosine phosphorylation of Pyk2 or Fak
in nonadherent RBL-2H3 mast cells (34, 39) and in Jurkat T cells (43,
47). Interestingly, PMA increased the tyrosine phosphorylation of Pyk2 and Fak in RBL-2H3 cells adherent to fibronectin, suggesting that PMA
enhances integrin-induced tyrosine phosphorylation of the PTKs (34,
39). Notably, although PKC depletion from PC12 cells or fibroblasts
markedly decreased PMA-induced tyrosine phosphorylation of Pyk2, it did
not affect receptor-induced tyrosine phosphorylation of the PTK in
those cells (25, 41). In contrast, depletion or inhibition of PKC
completely abolished SCF- and m1 muscarinic acetylcholine
receptor-induced tyrosine phosphorylation of Pyk2 in CMK megakaryotic
cells and in human embryonic kidney 293 cells, respectively (38, 44).
These results strongly suggest the existence of
PKC-dependent and PKC-independent pathways for the tyrosine
phosphorylation of Pyk2. We have shown here that depletion of
PMA-sensitive PKC did not block receptor-induced tyrosine
phosphorylation of Pyk2 in Jurkat T cells and that PKC activation by
PMA led to a marked reduction in TCR- and CD28-induced tyrosine
phosphorylation of the kinase. Thus, it appears that in different types
of cells, tyrosine phosphorylation of the focal adhesion PTKs is
differentially regulated and the role of PKC in the tyrosine
phosphorylation of focal adhesion PTKs is cell-specific.
Focal adhesion PTKs have been implicated in playing a role in linking
receptor-initiated signaling pathways to the MAPK cascades (31, 33, 35,
45). The focal adhesion PTKs are also associated constitutively with
cytoskeletal proteins such as paxillin and, therefore, could link
receptor-initiated signaling pathways with the cytoskeleton (35, 38,
56, 57). Pyk2 and Fak do not contain SH2 and SH3 binding domains;
therefore, the phosphorylation of these kinases on tyrosine is critical
for their interaction with the SH2 domains of other signaling
molecules. Accordingly, the tyrosine phosphorylation of Pyk2 and Fak
has been reported to result in the association of the PTKs with several
SH2-containing signaling molecules, including Src kinases and adaptor
molecules such as Grb2 (29, 30, 32, 33, 44). Thus, the
dephosphorylation of the focal adhesion PTKs upon PKC activation could
provide a mechanism for controlling the interaction of these PTKs with
other SH2-containing molecules and for regulating the function of the kinases in receptor-signaling in T cells.
In conclusion, our data identify a new mechanism for the regulation of
TCR and CD28 signaling by PKC, namely the regulation of Pyk2 and Fak
tyrosine phosphorylation. Our results also suggest that the regulation
of CD28 and TCR signaling by PKC involves protein tyrosine
phosphatases. These findings shed a light on our understanding of the
molecular mechanisms that regulate receptor-initiated signaling in T cells.
 |
ACKNOWLEDGEMENT |
We thank Andrea Schmick for editorial assistance.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: H4/749, Dept. of
Surgery, 600 Highland Ave., Madison, WI 53792. Tel.: 608-265-9149; Fax:
608265-9255; E-mail: hamawy@surgery.wisc.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
TCR, T cell
receptor;
Fak, focal adhesion kinase;
LAT, linker for activation of T
cells;
MAPK, mitogen-activated protein kinase;
PKC, protein kinase C;
PTK, protein tyrosine kinase;
PTPases, protein tyrosine phosphatases;
Pyk2, proline-rich tyrosine kinase 2;
SH, Src homology;
WCL, whole cell
lysate;
PMA, phorbol 12-myristate 13-acetate;
PAGE, polyacrylamide gel
electrophoresis;
mAb, monoclonal antibody;
BSA, bovine serum
albumin.
 |
REFERENCES |
| 1.
|
Qian, D.,
and Weiss, A.
(1997)
Curr. Opin. Cell Biol.
9,
205-212[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Chambers, C. A.,
and Allison, J. P.
(1997)
Curr. Opin. Immunol.
9,
396-404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Wange, R. L.,
and Samelson, L. E.
(1996)
Immunity
5,
197-205[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Werlen, G.,
Jacinto, E.,
Xia, Y.,
and Karin, M.
(1998)
EMBO J.
17,
3101-3111[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Mills, G. B.,
May, C.,
Hill, M.,
Ebanks, R.,
Roifman, C.,
Mellors, A.,
and Gelfand, E. W.
(1989)
J. Immunol.
142,
1995-2003[Abstract]
|
| 6.
|
Ledbetter, J. A.,
Imboden, J. B.,
Schieven, G. L.,
Grosmaire, L. S.,
Rabinovitch, P. S.,
Lindsten, T.,
Thompson, C. B.,
and June, C. H.
(1990)
Blood
75,
1531-1539[Abstract/Free Full Text]
|
| 7.
|
Abraham, R. T.,
Ho, S. N.,
Barna, T. J.,
Rusovick, K. M.,
and McKean, D. J.
(1988)
Mol. Cell. Biol.
8,
5448-5458[Abstract/Free Full Text]
|
| 8.
|
Isakov, N.,
and Altman, A.
(1987)
J. Immunol.
138,
3100-3107[Abstract]
|
| 9.
|
Park, D. J.,
Min, H. K.,
and Rhee, S. G.
(1992)
J. Biol. Chem.
267,
1496-1501[Abstract/Free Full Text]
|
| 10.
|
Ward, S. G.,
and Cantrell, D. A.
(1990)
J. Immunol.
144,
3523-3528[Abstract]
|
| 11.
|
Cantrell, D. A.,
Lucas, S. C.,
Ward, S.,
Westwick, J.,
and Gullberg, M.
(1989)
J. Immunol.
143,
3653-3658[Abstract]
|
| 12.
|
Hutchcroft, J. E.,
Tsai, B.,
and Bierer, B. E.
(1996)
J. Biol. Chem.
271,
13362-13370[Abstract/Free Full Text]
|
| 13.
|
Autero, M.,
and Gahmberg, C. G.
(1987)
Eur. J. Immunol.
17,
1503-1506[Medline]
[Order article via Infotrieve]
|
| 14.
|
Minami, Y.,
Samelson, L. E.,
and Klausner, R. D.
(1987)
J. Biol. Chem.
262,
13342-13347[Abstract/Free Full Text]
|
| 15.
|
Cantrell, D. A.,
Davies, A. A.,
and Crumpton, M. J.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
8158-8162[Abstract/Free Full Text]
|
| 16.
|
Hutchcroft, J. E.,
Franklin, D. P.,
Tsai, B.,
Harrison-Findik, D.,
Varticovski, L.,
and Bierer, B. E.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8808-8812[Abstract/Free Full Text]
|
| 17.
|
Parry, R. V.,
Boulougouris, G.,
Sansom, D. M.,
and Ward, S. G.
(1997)
Biochem. Soc. Trans.
25,
305
|
| 18.
|
Zhao, Z.,
Shen, S. H.,
and Fischer, E. H.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5007-5011[Abstract/Free Full Text]
|
| 19.
|
den Hertog, J.,
Sap, J.,
Pals, C. E.,
Schlessinger, J.,
and Kruijer, W.
(1995)
Cell Growth Differ.
6,
303-307[Abstract]
|
| 20.
|
Elson, A.,
and Leder, P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12235-12239[Abstract/Free Full Text]
|
| 21.
|
Flint, A. J.,
Gebbink, M. F.,
Franza, B. R. J.,
Hill, D. E.,
and Tonks, N. K.
(1993)
EMBO J.
12,
1937-1946[Medline]
[Order article via Infotrieve]
|
| 22.
|
Yamada, A.,
Streuli, M.,
Saito, H.,
Rothstein, D. M.,
Schlossman, S. F.,
and Morimoto, C.
(1990)
Eur. J. Immunol.
20,
1655-1660[Medline]
[Order article via Infotrieve]
|
| 23.
|
Hanks, S. K.,
Calalb, M. B.,
Harper, M. C.,
and Patel, S. K.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
8487-8491[Abstract/Free Full Text]
|
| 24.
|
Schaller, M. D.,
Borgman, C. A.,
Cobb, B. S.,
Vines, R. R.,
Reynolds, A. B.,
and Parsons, J. T.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
5192-5196[Abstract/Free Full Text]
|
| 25.
|
Lev, S.,
Moreno, H.,
Martinez, R.,
Canoll, P.,
Peles, E.,
Musacchio, J. M.,
Plowman, G. D.,
Rudy, B.,
and Schlessinger, J.
(1995)
Nature
376,
737-745[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Sasaki, H.,
Nagura, K.,
Ishino, M.,
Tobioka, H.,
Kotani, K.,
and Sasaki, T.
(1995)
J. Biol. Chem.
270,
21206-21219[Abstract/Free Full Text]
|
| 27.
|
Avraham, S.,
London, R.,
Fu, Y.,
Ota, S.,
Hiregowdara, D.,
Li, J.,
Jiang, S.,
Pasztor, L. M.,
White, R. A.,
and Groopman, J. E.
(1995)
J. Biol. Chem.
270,
27742-27751[Abstract/Free Full Text]
|
| 28.
|
Yu, H.,
Li, X.,
Marchetto, G. S.,
Dy, R.,
Hunter, D.,
Calvo, B.,
Dawson, T. L.,
Wilm, M.,
Anderegg, R. J.,
Graves, L. M.,
and Earp, H. S.
(1996)
J. Biol. Chem.
271,
29993-29998[Abstract/Free Full Text]
|
| 29.
|
Li, J. Z.,
Avraham, H.,
Rogers, R. A.,
Raja, S.,
and Avraham, S.
(1996)
Blood
88,
417-428[Abstract/Free Full Text]
|
| 30.
|
Ganju, R. K.,
Hatch, W. C.,
Avraham, H.,
Ona, M. A.,
Druker, B.,
Avraham, S.,
and Groopman, J. E.
(1997)
J. Exp. Med.
185,
1055-1063[Abstract/Free Full Text]
|
| 31.
|
Tokiwa, G.,
Dikic, I.,
Lev, S.,
and Schlessinger, J.
(1996)
Science
273,
792-794[Abstract]
|
| 32.
|
Qian, D. P.,
Lev, S.,
Vanoers, N. C.,
Dikic, I.,
Schlessinger, J.,
and Weiss, A.
(1997)
J. Exp. Med.
185,
1253-1259[Abstract/Free Full Text]
|
| 33.
|
Dikic, I.,
Tokiwa, G.,
Lev, S.,
Courtneidge, S. A.,
and Schlessinger, J.
(1996)
Nature
383,
547-550[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Okazaki, H.,
Zhang, J.,
Hamawy, M. M.,
and Siraganian, R. P.
(1997)
J. Biol. Chem.
272,
32443-32447[Abstract/Free Full Text]
|
| 35.
|
Ganju, R. K.,
Dutt, P.,
Wu, L. J.,
Newman, W.,
Avraham, H.,
Avraham, S.,
and Groopman, J. E.
(1998)
Blood
91,
791-797[Abstract/Free Full Text]
|
| 36.
|
Hatch, W. C.,
Ganju, R. K.,
Hiregowdara, D.,
Avraham, S.,
and Groopman, J. E.
(1998)
Blood
91,
3967-3973[Abstract/Free Full Text]
|
| 37.
|
Astier, A.,
Avraham, H.,
Manie, S. N.,
Groopman, J.,
Canty, T.,
Avraham, S.,
and Freedman, A. S.
(1997)
J. Biol. Chem.
272,
228-232[Abstract/Free Full Text]
|
| 38.
|
Hiregowdara, D.,
Avraham, H.,
Fu, Y. G.,
London, R.,
and Avraham, S.
(1997)
J. Biol. Chem.
272,
10804-10810[Abstract/Free Full Text]
|
| 39.
|
Hamawy, M. M.,
Mergenhagen, S. E.,
and Siraganian, R. P.
(1993)
J. Biol. Chem.
268,
6851-6854[Abstract/Free Full Text]
|
| 40.
|
Hamawy, M. M.,
Swieter, M.,
Mergenhagen, S. E.,
and Siraganian, R. P.
(1997)
J. Biol. Chem.
272,
30498-30503[Abstract/Free Full Text]
|
| 41.
|
Sinnett-Smith, J.,
Zachary, I.,
Valverde, A. M.,
and Rozengurt, E.
(1993)
J. Biol. Chem.
268,
14261-14268[Abstract/Free Full Text]
|
| 42.
|
Lipfert, L.,
Haimovich, B.,
Schaller, M. D.,
Cobb, B. S.,
Parsons, J. T.,
and Brugge, J. S.
(1992)
J. Cell Biol.
119,
905-912[Abstract/Free Full Text]
|
| 43.
|
Maguire, J. E.,
Danahey, K. M.,
Burkly, L. C.,
and van Seventer, G. A.
(1995)
J. Exp. Med.
182,
2079-2090[Abstract/Free Full Text]
|
| 44.
|
Felsch, J. S.,
Cachero, T. G.,
and Peralta, E. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
5051-5056[Abstract/Free Full Text]
|
| 45.
|
Schlaepfer, D. D.,
Hanks, S. K.,
Hunter, T.,
and van der Geer, P.
(1994)
Nature
372,
786-791[Medline]
[Order article via Infotrieve]
|
| 46.
|
van Seventer, G. A.,
Mullen, M. M.,
and Vanseventer, J. M.
(1998)
Eur. J. Immunol.
28,
3867-3877[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Tsuchida, M.,
Knechtle, S. J.,
and Hamawy, M. M.
(1999)
J. Biol. Chem.
274,
6735-6740[Abstract/Free Full Text]
|
| 48.
|
Tsuchida, M.,
Manthei, E. R.,
Knechtle, S. J.,
and Hamawy, M. M.
(1999)
Eur. J. Immunol.
29,
2354-2359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Fechner, J. H. J.,
Vargo, D. J.,
Geissler, E. K.,
Graeb, C.,
Wang, J.,
Hanaway, M. J.,
Watkins, D. I.,
Piekarczyk, M.,
Neville, D. M. J.,
and Knechtle, S. J.
(1997)
Transplantation
63,
1339-1345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Zhang, W.,
Sloan-Lancaster, J.,
Kitchen, J.,
Trible, R. P.,
and Samelson, L. E.
(1998)
Cell
92,
83-92[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Cobb, B. S.,
Schaller, M. D.,
Leu, T. H.,
and Parsons, J. T.
(1994)
Mol. Cell. Biol.
14,
147-155[Abstract/Free Full Text]
|
| 52.
|
Gould, K. L.,
Woodgett, J. R.,
Cooper, J. A.,
Buss, J. E.,
Shalloway, D.,
and Hunter, T.
(1985)
Cell
42,
849-857[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Purchio, A. F.,
Shoyab, M.,
and Gentry, L. E.
(1985)
Science
229,
1393-1395[Abstract/Free Full Text]
|
| 54.
|
Veillette, A.,
Horak, I. D.,
and Bolen, J. B.
(1988)
Oncogene Res.
2,
385-401[Medline]
[Order article via Infotrieve]
|
| 55.
|
Casnellie, J. E.,
and Lamberts, R. J.
(1986)
J. Biol. Chem.
261,
4921-4925[Abstract/Free Full Text]
|
| 56.
|
Hildebrand, J. D.,
Schaller, M. D.,
and Parsons, J. T.
(1995)
Mol. Biol. Cell
6,
637-647[Abstract]
|
| 57.
|
Ostergaard, H. L.,
Lou, O.,
Arendt, C. W.,
and Berg, N. N.
(1998)
J. Biol. Chem.
273,
5692-5696[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
B. Butler and S. D. Blystone
Tyrosine Phosphorylation of {beta}3 Integrin Provides a Binding Site for Pyk2
J. Biol. Chem.,
April 15, 2005;
280(15):
14556 - 14562.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Y. Romanova, S. Hashimoto, K.-O. Chay, M. V. Blagosklonny, H. Sabe, and J. F. Mushinski
Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive
J. Cell Sci.,
August 1, 2004;
117(17):
3759 - 3768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Maher
How Protein Kinase C Activation Protects Nerve Cells from Oxidative Stress-Induced Cell Death
J. Neurosci.,
May 1, 2001;
21(9):
2929 - 2938.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|